Thanks OvF, can you please expand on your last sentence, "Maybe some patients are doing too well & this appears to now be the norm on Onco trials that have shown benefit like we have & cut short by a DSMB review & independent data PFS review."?
I assume you mean OS shows comparatively better than PFS in onco trials? Would you mind pointing to some of those, and any that you know of been cut short due to benefit?
I'm just always curious to learn.
Cheers.
Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-159
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $93.42K | 1.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 7631372 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2885344 | 22 |
View Market Depth
| Last trade - 10.59am 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |